USD 7.88
(1.39%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 165.5 Million USD | -56.03% |
2022 | 376.42 Million USD | -19.59% |
2021 | 468.12 Million USD | -20.4% |
2020 | 588.12 Million USD | 71.49% |
2019 | 342.94 Million USD | -12.48% |
2018 | 391.83 Million USD | 79.93% |
2017 | 217.77 Million USD | -17.48% |
2016 | 263.91 Million USD | -18.79% |
2015 | 324.97 Million USD | 206.23% |
2014 | 106.12 Million USD | 104.76% |
2013 | 51.82 Million USD | 1108.11% |
2012 | 4.29 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 117.28 Million USD | -29.04% |
2024 Q1 | 165.27 Million USD | -0.14% |
2023 Q1 | 302.08 Million USD | -19.75% |
2023 Q3 | 188.78 Million USD | -23.39% |
2023 FY | 165.5 Million USD | -56.03% |
2023 Q4 | 165.5 Million USD | -12.33% |
2023 Q2 | 246.43 Million USD | -18.42% |
2022 Q1 | 397.28 Million USD | -15.13% |
2022 Q3 | 368.31 Million USD | -15.55% |
2022 Q2 | 436.12 Million USD | 9.78% |
2022 FY | 376.42 Million USD | -19.59% |
2022 Q4 | 376.42 Million USD | 2.2% |
2021 Q2 | 456.79 Million USD | -13.75% |
2021 FY | 468.12 Million USD | -20.4% |
2021 Q1 | 529.63 Million USD | -9.94% |
2021 Q4 | 468.12 Million USD | 4.05% |
2021 Q3 | 449.92 Million USD | -1.5% |
2020 Q2 | 428.11 Million USD | 42.92% |
2020 Q4 | 588.12 Million USD | 45.02% |
2020 FY | 588.12 Million USD | 71.49% |
2020 Q3 | 405.53 Million USD | -5.27% |
2020 Q1 | 299.54 Million USD | -12.65% |
2019 Q4 | 342.94 Million USD | -5.99% |
2019 Q3 | 364.78 Million USD | 33.06% |
2019 Q2 | 274.14 Million USD | -15.58% |
2019 Q1 | 324.72 Million USD | -17.13% |
2019 FY | 342.94 Million USD | -12.48% |
2018 FY | 391.83 Million USD | 79.93% |
2018 Q4 | 391.83 Million USD | -11.54% |
2018 Q3 | 442.94 Million USD | -10.1% |
2018 Q2 | 492.7 Million USD | 4.14% |
2018 Q1 | 473.1 Million USD | 117.24% |
2017 FY | 217.77 Million USD | -17.48% |
2017 Q2 | 244.15 Million USD | 1.0% |
2017 Q3 | 229.69 Million USD | -5.92% |
2017 Q1 | 241.73 Million USD | -8.4% |
2017 Q4 | 217.77 Million USD | -5.19% |
2016 Q1 | 312.97 Million USD | -3.69% |
2016 FY | 263.91 Million USD | -18.79% |
2016 Q4 | 263.91 Million USD | -7.21% |
2016 Q3 | 284.41 Million USD | -5.45% |
2016 Q2 | 300.81 Million USD | -3.89% |
2015 Q3 | 340.37 Million USD | 111.28% |
2015 Q2 | 161.1 Million USD | -5.13% |
2015 Q1 | 169.81 Million USD | 60.02% |
2015 FY | 324.97 Million USD | 206.23% |
2015 Q4 | 324.97 Million USD | -4.53% |
2014 Q1 | 62.86 Million USD | 21.3% |
2014 Q3 | 54.12 Million USD | -7.49% |
2014 Q2 | 58.5 Million USD | -6.94% |
2014 FY | 106.12 Million USD | 104.76% |
2014 Q4 | 106.12 Million USD | 96.09% |
2013 Q4 | 51.82 Million USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | 51.82 Million USD | 1108.11% |
2012 FY | 4.29 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
uniQure N.V. | 831.68 Million USD | 80.1% |
Abeona Therapeutics Inc. | 64 Million USD | -158.592% |
Aclaris Therapeutics, Inc. | 197.4 Million USD | 16.16% |
Agios Pharmaceuticals, Inc. | 937.11 Million USD | 82.339% |
Cara Therapeutics, Inc. | 125.84 Million USD | -31.515% |
Imunon, Inc. | 21.91 Million USD | -655.103% |
Dynavax Technologies Corporation | 997.09 Million USD | 83.401% |
Editas Medicine, Inc. | 499.15 Million USD | 66.843% |
FibroGen, Inc. | 423.52 Million USD | 60.923% |
Iovance Biotherapeutics, Inc. | 780.35 Million USD | 78.791% |
Kala Pharmaceuticals, Inc. | 55.94 Million USD | -195.812% |
Neurocrine Biosciences, Inc. | 3.25 Billion USD | 94.91% |
Sarepta Therapeutics, Inc. | 3.26 Billion USD | 94.93% |
Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 88.254% |
Verastem, Inc. | 149.71 Million USD | -10.544% |
Zoetis Inc. | 14.28 Billion USD | 98.841% |
Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.272% |
Sangamo Therapeutics, Inc. | 165.32 Million USD | -0.111% |
Homology Medicines, Inc. | 47.05 Million USD | -251.71% |
Nektar Therapeutics | 398.03 Million USD | 58.42% |
Viking Therapeutics, Inc. | 368.49 Million USD | 55.086% |
Unity Biotechnology, Inc. | 65.69 Million USD | -151.947% |
Perrigo Company plc | 10.8 Billion USD | 98.469% |
Esperion Therapeutics, Inc. | 205.79 Million USD | 19.579% |
Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.796% |
Illumina, Inc. | 10.11 Billion USD | 98.363% |
Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.832% |
IQVIA Holdings Inc. | 26.68 Billion USD | 99.38% |
Heron Therapeutics, Inc. | 222.5 Million USD | 25.618% |
Waters Corporation | 4.62 Billion USD | 96.423% |
Biogen Inc. | 26.84 Billion USD | 99.383% |
Evolus, Inc. | 188.99 Million USD | 12.431% |
Adicet Bio, Inc. | 207.29 Million USD | 20.16% |
bluebird bio, Inc. | 619.16 Million USD | 73.27% |
Geron Corporation | 394.07 Million USD | 58.002% |
Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 95.679% |
Amicus Therapeutics, Inc. | 777.88 Million USD | 78.724% |
Myriad Genetics, Inc. | 1.19 Billion USD | 86.193% |
Intellia Therapeutics, Inc. | 1.3 Billion USD | 87.278% |
Mettler-Toledo International Inc. | 3.35 Billion USD | 95.068% |
Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -485.391% |
BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 97.581% |
Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.5% |
Agilent Technologies, Inc. | 10.76 Billion USD | 98.462% |
OPKO Health, Inc. | 2.01 Billion USD | 91.773% |
Exelixis, Inc. | 2.94 Billion USD | 94.375% |
Corcept Therapeutics Incorporated | 621.51 Million USD | 73.371% |
Anavex Life Sciences Corp. | 154.38 Million USD | -7.201% |
Axsome Therapeutics, Inc. | 588.23 Million USD | 71.864% |
Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 94.465% |
Halozyme Therapeutics, Inc. | 1.73 Billion USD | 90.451% |
Blueprint Medicines Corporation | 1.04 Billion USD | 84.226% |
Insmed Incorporated | 1.32 Billion USD | 87.555% |
TG Therapeutics, Inc. | 329.58 Million USD | 49.784% |
Incyte Corporation | 6.78 Billion USD | 97.56% |
Emergent BioSolutions Inc. | 1.83 Billion USD | 90.98% |